Last reviewed · How we verify
Lyophilized mepolizumab
Mepolizumab is a monoclonal antibody that binds to interleukin-5 (IL-5) and prevents its interaction with eosinophils, reducing eosinophil production and activation.
Mepolizumab is a monoclonal antibody that binds to interleukin-5 (IL-5) and prevents its interaction with eosinophils, reducing eosinophil production and activation. Used for Severe eosinophilic asthma, Eosinophilic granulomatosis with polyangiitis (EGPA), Chronic rhinosinusitis with nasal polyps (eosinophilic phenotype).
At a glance
| Generic name | Lyophilized mepolizumab |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Monoclonal antibody; IL-5 antagonist |
| Target | IL-5 (Interleukin-5) |
| Modality | Biologic |
| Therapeutic area | Immunology; Respiratory |
| Phase | Phase 3 |
Mechanism of action
Mepolizumab targets IL-5, a key cytokine involved in eosinophil development, recruitment, and survival. By neutralizing IL-5, the drug reduces circulating and tissue eosinophil levels, thereby decreasing eosinophil-mediated inflammation. This mechanism is particularly effective in eosinophil-driven inflammatory conditions such as severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA).
Approved indications
- Severe eosinophilic asthma
- Eosinophilic granulomatosis with polyangiitis (EGPA)
- Chronic rhinosinusitis with nasal polyps (eosinophilic phenotype)
Common side effects
- Headache
- Nasopharyngitis
- Injection site reactions
- Pyrexia
Key clinical trials
- Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma (PHASE4)
- A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma (PHASE3)
- Mepolizumab in Episodic Angioedema With Eosinophilia (PHASE2)
- Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 (PHASE3)
- Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis (PHASE2)
- Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) (PHASE3)
- A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised Drug (PHASE3)
- A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lyophilized mepolizumab CI brief — competitive landscape report
- Lyophilized mepolizumab updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI